Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Amandeep Kaur, Anupamjeet Kaur, Deepti Goyal, Bhupesh Goyal
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Aggregation of disease–related peptides
10.1016/bs.pmbts.2019.12.002 · 2020
Über Eine Eigenartige Erkrankung Der Hirnrinde
1907
Unresolved referenced work
Kept as external metadata until matched
Ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer’s disease
10.1016/j.trci.2019.11.007 · 2019
Rates of age– and amyloid β–associated cortical atrophy in older adults with superior memory performance
10.1016/j.dadm.2019.05.005 · 2019
Family history is associated with phenotype in dementia with lewy bodies
10.3233/jad-190825 · 2020
2020 Alzheimer’s disease facts and figures
10.1002/alz.12068 · 2020
Amyloid β–protein and beyond: the path forward in Alzheimer’s disease
10.1016/j.conb.2020.02.003 · 2020
A critical appraisal of amyloid−β-targeting therapies for Alzheimer disease
10.1038/s41582-018-0116-6 · 2019
The amyloid beta peptide: a chemist’s perspective. Role in Alzheimer’s and fibrillization
10.1021/cr3000994 · 2012
Methodological and chemical factors affecting amyloid beta peptide amyloidogenicity
10.1016/s0076-6879(99)09015-1 · 1999
Characterizing the structural and thermodynamic properties of Aβ42 and Aβ40
10.1016/j.bbrc.2019.01.124 · 2019
Mechanisms of amyloid fibril formation by proteins
2010
Fundamentals of cross–seeding of amyloid proteins: an introduction
10.1039/c9tb01871a · 2019
Molecular simulation aspects of amyloid peptides at membrane interface
10.1016/j.bbamem.2018.02.004 · 2018
Rational design of a cocktail of inhibitors against Aβ aggregation
10.1002/chem.201905621 · 2020
Ginnalin a inhibits aggregation, reverses fibrillogenesis, and alleviates cytotoxicity of amyloid β(1–42)
10.1021/acschemneuro.9b00673 · 2020
Impact of the astaxanthin, betanin and EGCG compounds on small oligomers of amyloid Aβ40 peptide
10.1021/acs.jcim.9b01074 · 2020
Interactions between curcumin derivatives and amyloid−β fibrils: insights from molecular dynamics simulations
10.1021/acs.jcim.9b00561 · 2019
Small molecules as therapeutic drugs for Alzheimer’s disease
10.1016/j.mcn.2019.03.001 · 2019
10.1016/j.bioorg.2019.03.058
10.1016/j.bioorg.2019.03.058 · 2019
Benzofuran and indole: promising scaffolds for drug development in Alzheimer’s disease
10.1002/cmdc.201800156 · 2018
Inhibition of β–amyloid channels with a drug candidate wgx–50 revealed by molecular dynamics simulations
10.1021/acs.jcim.7b00452 · 2017
Inhibition of protein aggregation and amyloid formation by small molecules
10.1016/j.sbi.2014.12.004 · 2015
Small–molecule inhibitors/modulators of amyloid−β peptide aggregation and toxicity for the treatment of Alzheimer’s disease: a patent review (2010–2012)
10.1517/13543776.2013.772983 · 2013
Molecular dynamics simulations reveal the mechanism of graphene oxide nanosheet inhibition of Aβ1–42 peptide aggregation
10.1039/c9cp01803d · 2019
Impact of nanoparticles on amyloid peptide and protein aggregation: a review with a focus on gold nanoparticles
10.1039/c8nr04506b · 2018
Destruction of amyloid fibrils by graphene through penetration and extraction of peptides
10.1039/c5nr01172h · 2015
Molecular modeling approach to explore the role of cathepsin B from Hordeum vulgare in the degradation of Aβ peptides
10.1039/c5mb00718f · 2016
An aminopeptidase from Streptomyces sp. KK565 degrades beta amyloid monomers, oligomers and fibrils
10.1016/j.febslet.2010.08.048 · 2010
Peptide-based molecular strategies to interfere with protein misfolding, aggregation and cell degeneration
10.1002/anie.201906908 · 2020
Peptides, peptidomimetics, and carbohydrate–peptide conjugates as amyloidogenic aggregation inhibitors for Alzheimer’s disease
10.1021/acschemneuro.8b00185 · 2018
Peptides as potential therapeutics for Alzheimer’s disease
10.3390/molecules23020283 · 2018
Rationally designed peptides and peptidomimetics as inhibitors of amyloid−β (Aβ) aggregation: potential therapeutics of Alzheimer’s disease
10.1021/acscombsci.6b00116 · 2017
Nature–inspired design and evolution of anti–amyloid antibodies
10.1074/jbc.ra118.004731 · 2019
Structure–based design of conformation–and sequence–specific antibodies against amyloid
10.1073/pnas.1111232108 · 2012
Alzheimer’s disease drug development pipeline: 2019
10.1016/j.trci.2019.05.008 · 2019
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Curcumin binds to Aβ1–40 peptides and fibrils stronger than ibuprofen and naproxen
10.1021/jp302506a · doi-reference
12-Crown-4 ether disrupts the patient brain-derived amyloid-β-fibril trimer: Insight from all-atom molecular dynamics simulations
10.1021/acschemneuro.6b00185 · doi-reference
Dihydrochalcone molecules destabilize Alzheimer’s amyloid-β protofibrils through binding to the protofibril cavity
10.1039/c8cp01631c · doi-reference
Structural and fluctuational difference between two ends of Aβ amyloid fibril: MD simulations predict only one end has open conformations
10.1038/srep38422 · doi-reference
Fibril elongation by Aβ17–42: kinetic network analysis of hybrid-resolution molecular dynamics simulations
10.1021/ja507002p · doi-reference
Toxic species in amyloid disorders: oligomers or mature fibrils
10.4103/0972-2327.144284 · doi-reference
Computational studies of protein aggregation: methods and applications
10.1146/annurev-physchem-040513-103738 · doi-reference
Mechanisms of amyloid formation revealed by solution NMR
10.1016/j.pnmrs.2015.05.002 · doi-reference
NMR–based site–resolved profiling of β–amyloid misfolding reveals structural transitions from pathologically relevant spherical oligomer to fibril
10.1074/jbc.ra119.008522 · doi-reference
Structural heterogeneity in familial Alzheimer’s disease mutants of amyloid–beta peptides
10.1039/c2mb25457c · doi-reference
Molecular structural basis for polymorphism in Alzheimer’s β–amyloid fibrils
10.1073/pnas.0806270105 · doi-reference
Structure–based peptide design to modulate amyloid beta aggregation and reduce cytotoxicity
10.1371/journal.pone.0129087 · doi-reference
A key role for lysine residues in amyloid β-protein folding, assembly, and toxicity
10.1021/cn3000247 · doi-reference
Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis
10.1006/jmbi.2001.4970 · doi-reference
Homogeneous and heterogeneous tertiary structure ensembles of amyloid–β peptides
10.1021/bi200732x · doi-reference
Solution NMR studies of the Aβ(1–40) and Aβ(1–42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation
10.1021/ja036813f · doi-reference
Contact electron–spin coupling of nuclear magnetic moments
10.1063/1.1729860 · doi-reference
Criterion for orbital hybridization and charge distribution in chemical bonds
10.1073/pnas.45.8.1269 · doi-reference
SHIFTX2: significantly improved protein chemical shift prediction
10.1007/s10858-011-9478-4 · doi-reference
Are current molecular dynamics force fields too helical?
10.1529/biophysj.108.132696 · doi-reference
Molecular mechanism of the inhibition of EGCG on the Alzheimer Aβ1-42 dimer
10.1021/jp312573y · doi-reference
g_mmpbsa– a GROMACS tool for high–throughput MM–PBSA calculations
10.1021/ci500020m · doi-reference
The MM/PBSA and MM/GBSA methods to estimate ligand–binding affinities
10.1517/17460441.2015.1032936 · doi-reference
Peptide folding: when simulation meets experiment
10.1002/(sici)1521-3773(19990115)38:1/2<236::aid-anie236>3.0.co;2-m · doi-reference
Dictionary of protein secondary structure: pattern recognition of hydrogen–bonded and geometrical features
10.1002/bip.360221211 · doi-reference
VMD: Visual molecular dynamics
10.1016/0263-7855(96)00018-5 · doi-reference
Polymorphic transitions in single crystals: A new molecular dynamics method
10.1063/1.328693 · doi-reference
Molecular dynamics with coupling to an external bath
10.1063/1.448118 · doi-reference
Canonical sampling through velocity rescaling
10.1063/1.2408420 · doi-reference
LINCS: A linear constraint solver for molecular simulations
10.1002/(sici)1096-987x(199709)18:12<1463::aid-jcc4>3.0.co;2-h · doi-reference
Particle mesh Ewald: An N.log(N) method for Ewald sums in large systems
10.1063/1.464397 · doi-reference
A smooth particle mesh Ewald method
10.1063/1.470117 · doi-reference
Destabilization of Alzheimer’s Aβ42 protofibrils with a novel drug candidate wgx–50 by molecular dynamics simulations
10.1021/acs.jpcb.5b03116 · doi-reference
Compound CID 9998128 is a potential multitarget drug for Alzheimer’s disease
10.1021/acschemneuro.8b00091 · doi-reference
Effect of familial mutations on the interconversion of α–helix to β–sheet structures in an amyloid–forming peptide: insight from umbrella sampling simulations
10.1021/acschemneuro.8b00425 · doi-reference
Interaction models for water in relation to protein hydration
10.1007/978-94-015-7658-1_21 · doi-reference
Ring–like N–fold models of Aβ42 fibrils
10.1038/s41598-017-06846-0 · doi-reference
Inhibition mechanisms of a pyridazine–based amyloid inhibitor: as a β–sheet destabilizer and a helix bridge maker
10.1021/acs.jpcb.7b05189 · doi-reference
Binding of 12–Crown–4 with Alzheimer’s Aβ40 and Aβ42 monomers and its effect on their conformation: insight from molecular dynamics simulations
10.1021/acs.molpharmaceut.7b00966 · doi-reference
Cell size effects in the molecular dynamics of the intrinsically disordered Aβ peptide
10.1063/1.5115085 · doi-reference